Core Viewpoint - Nutriband has successfully completed the commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, in partnership with Kindeva, marking a significant milestone towards developing a commercially viable abuse-deterrent fentanyl patch [1][3]. Group 1: Product Development - Aversa™ Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, and is manufactured at Kindeva's advanced transdermal facility in the United States [2]. - The next steps include manufacturing clinical supplies and filing an Investigational New Drug (IND) application with the FDA to initiate a human abuse liability clinical study [2]. Group 2: Market Potential - Aversa Fentanyl has the potential to be the first abuse-deterrent opioid patch on the market, aimed at deterring abuse and reducing accidental exposure risks, with projected peak annual US sales between $80 million to $200 million [5]. - The company plans to initially focus on the US market while also targeting global markets due to the widespread unmet medical need for effective pain management [5]. Group 3: Technology and Intellectual Property - Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent drug abuse, ensuring that these medications remain accessible to patients in need [4][7]. - The technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including major markets such as the United States, Europe, and China [6][7].

Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transderma ...

Core Insights - Nutriband Inc. has received a patent grant in Macao for its AVERSA™ abuse deterrent transdermal technology, enhancing its intellectual property portfolio [1][2][3] - The AVERSA™ technology aims to prevent the abuse and misuse of drugs, particularly opioids, while ensuring accessibility for patients in need [4][6] - The company is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which could potentially achieve peak annual US sales between $80 million and $200 million [5][6] Intellectual Property - The patent J/9010 was granted on February 11, 2025, and is part of a broader international portfolio covering 46 countries, including major markets like the US, Europe, and China [2][3] - Macao's patent system operates independently from mainland China's, providing a unique advantage for Nutriband's technology [2] Product Development - AVERSA™ technology incorporates aversive agents into transdermal patches to mitigate risks associated with drug abuse, including accidental exposure [4][6] - The lead product under development is an abuse-deterrent fentanyl patch, which is designed to be the first of its kind in the market [5][6] Market Potential - The AVERSA™ Fentanyl patch is positioned to address significant market needs in opioid management, with a substantial projected sales range indicating strong market interest [6]